William Blair Analysts Raise Earnings Estimates for IQVIA

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Equities research analysts at William Blair boosted their Q4 2024 earnings per share estimates for shares of IQVIA in a research note issued on Wednesday, December 11th. William Blair analyst M. Smock now anticipates that the medical research company will earn $2.83 per share for the quarter, up from their previous forecast of $2.82. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for IQVIA's current full-year earnings is $10.18 per share. William Blair also issued estimates for IQVIA's Q1 2025 earnings at $2.37 EPS.

Other analysts also recently issued reports about the stock. The Goldman Sachs Group cut their price objective on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th. Leerink Partners reaffirmed an "outperform" rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $256.19.

IQVIA Stock Down 1.0 %

Shares of NYSE IQV traded down $1.97 during trading on Monday, reaching $197.09. The company had a trading volume of 1,804,661 shares, compared to its average volume of 1,188,671. The business's 50-day moving average is $212.24 and its 200 day moving average is $224.20. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $35.77 billion, a PE ratio of 26.12, a P/E/G ratio of 2.05 and a beta of 1.49. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the third quarter valued at $27,000. Park Place Capital Corp purchased a new stake in IQVIA in the 3rd quarter valued at about $28,000. Itau Unibanco Holding S.A. bought a new position in IQVIA in the 2nd quarter worth about $29,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $32,000. Finally, Avior Wealth Management LLC boosted its holdings in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.